key: cord-0983941-cu3nx44w
authors: Wu, Daniel; Wang, Victoria Y.; Chen, Ya-Hui; Ku, Chih-Hung; Wang, Pa-Chun
title: The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 - A Systematic Review
date: 2021-07-15
journal: Auris Nasus Larynx
DOI: 10.1016/j.anl.2021.07.007
sha: c89b3d1dcebaa117ad34fa54070b4e51b9514607
doc_id: 983941
cord_uid: cu3nx44w

OBJECTIVES: Loss of smell or taste are early symptoms of COVID-19. Given the high asymptomatic rate of COVID-19, as well as unreliable temperature checking and contact history taking, it is important to understand the role of olfactory and gustatory dysfunction (OGD) in the diagnosis of COVID-19. The aim of this study is to determine how initial symptoms of OGD can be used to screen patients for COVID-19 laboratory testing. METHODS: We followed recommendations from the Preferred Reporting Items for Systemic Reviews and Meta-analysis (PRISMA) statement to conduct this systematic review study. We used OGD-related key words to search for literature published between January 1, 2020 and September 30, 2020 on Pubmed, Ovid Medline databases. We estimated the prevalence of OGD and compared it with that of other OGD-related symptoms. The weighted summary proportion under the fixed and random effects model was assessed using MedCalc statistical software. Whenever there was heterogeneity, a random effects model was selected. Publication bias was assessed by funnel plot asymmetry and Egger's regression test. RESULTS: A total of 25 articles (evidence level III:5; IV:20) were identified and reviewed. Data synthesis of 19 articles revealed that the pooled prevalence of olfactory dysfunction in COVID-19 is 53.56% (range 5.6-100%, 95% CI 40.25-66.61%). The pooled prevalence of gustatory dysfunction in COVID-19 is 43.93% (range 1.5-85.18%, 95% CI 28.72-59.74%), just behind fever (62.22%, range 18.18-95.83%, 95% CI 54.82-69.33%), cough (64.74%, range 38.89-87.5%, 95% CI 57.97-71.22%), and fatigue (56.74%, range 6.25-93.62%, 95% CI 32.53-79.35%). The prevalence of gustatory dysfunction in subgroup with objective evaluation is lower than those without (9.91% vs. 49.21%, relive risk 2.82, p<0.001). CONCLUSION: Our updated systematic review attests that OGD is an important early symptom of COVID-19 infection. Screening for OGD should be further emphasized to prioritize patients for laboratory test.

Coronavirus disease 2019 (COVID- 19) is an airway infectious disease that was first identified in December 2019. The single-stranded RNA (ssRNA) severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) is believed to have evolved from a viral strain found in bats [1] [2] [3] . Since the first COVID-19 case was identified, the outbreak has spread globally through international travel. To date, the pandemic shows little sign of ease; globally, billion people have been infected, and mortality is still on the rise to cause tremendous impacts on public health, economy, and society.

Diagnosis of COVID-19 relies on the detection of nucleic acid or antigen from either sputum or saliva, via nasal or oral swabbing. The reverse transcription-polymerase chain reaction (RT-PCR) is the test of choice for COVID-19 [1] . Antibody testing can be conducted in conjunction with viral testing in some cases to identify previous COVID-19 infection. However, even though laboratory and point-of-care (POC) tests are readily available on the market, many countries with high prevalence have encountered challenges related to laboratory capacity exhaustion. A stratified or targeted screening strategy can aid in the early identification of high-risk patients, and also optimize laboratory capacity utilization.

The clinical courses of COVID-19 and SARS are similar in many ways [2] [3] ; patients are contagious early on in the disease course, and early clinical symptoms include fever, cough, fatigue, and dyspnea, which are also seen in seasonal flus. However, one big difference seen in COVID-19 is the high number of asymptomatic and mild cases; these patients don't usually have high fevers, as seen in SARS, which makes screening and prevention difficult.

Fortunately, studies have documented symptoms of COVID-19 manifesting in a predictable order. Influenza infection often begins with cough, then fever. In contrast, SARS, Middle East Respiratory Syndrome (MERS), and COVID-19 tend to start with fever, then progress to cough and muscle pain. COVID-19 may also present with nausea and vomiting before diarrhea [4] . Understanding the symptomatology of COVID-19 can help identify important early warning signs to prevent potential community transmission.

Since Mao et al. reported the neurological manifestations of 214 COVID-19 patients [5] [6] , there has been increasing image-based evidence to support the neurological involvement of COVID-19. Olfactory and gustatory dysfunction (OGD) are atypical symptoms that have drawn attention during the COVID-19 pandemic. In Mao's study, 5.1% anosmia and 5.6% ageusia were reported [5] . There is speculation that the virus may attack the CNS through retrograde olfactory pathways. Imaging studies confirm a high percentage of patients with increased olfactory cleft width and volume, indicative of olfactory bulb degeneration that is predisposed to viral upper airway infection, similar to other postviral infection olfactory loss. [7, 8, 9] . In two systematic reviews, pooled data demonstrated that the prevalence of OGD among COVID-19 patients may be as high as 41.0~52.73% and 38.2~52.73%, respectively [10, 11] . As such, the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) established the COVID-19 Anosmia Reporting Tool for Clinician [12] . The initial report identified 73% prevalence of anosmia in COVID-19 patients, with 26.6% of patients experiencing anosmia as the initial symptom [13] .

It would seem that OGD are symptoms that have predictive value in the early identification of potential COVID-19 patients in the community. Given the rapidly accumulated evidences and heterogeneity of existing data, it is critical to consistently update our knowledge base. We hypothesize that, next to fever, OGD are predictive initial symptoms that can be used to refer patients for COVID-19 laboratory testing. In this study, we performed qualitative and quantitative analyses on collective data.

We followed recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement [14] to conduct this systematic review.

On PubMed and Ovid Medline databases, we entered the search string "anosmia or hyposmia or dysosmia or olfactory dysfunction or olfaction disorder or smell dysfunction or ageusia or hypogeusia or dysgeusia or taste dysfunction or gustatory dysfunction and COVID-19 or SARS-CoV-2" in either the "title" or "abstract" fields to search for literature published between 

We included peer-reviewed scientific papers reporting the prevalence of OGD in patients with confirmed COVID-19 infection. Studies needed to be available in the full-text version to be included. We also used PubMed's "related link" function to extend our search manually.

Only English publications related to human studies (i.e. no animal or laboratory studies) were included. We excluded publications in the categories "letter to editor," "opinion," "editorial," "case report," and "systematic review." Search output duplicates were verified and excluded.

The search flowchart is shown in Fig. 1 .

The queried publications' quality was assessed (PCW, YHC) using the bias checklist developed by Hoy et al [15] . The checklist uses 9 items (representativeness of national population, representativeness of targeted population, use of randomization, non-response rate, data source, case definition, reliability and validity of measurement, mode of data collection, clarity of numerator and denominator) to evaluate study quality (risk of bias), and generates a total risk score ranging from low (0-3), moderate (4) (5) (6) , to high (7) (8) (9) . The distribution of quality scores of the EARLY (published before May 31, 2020) and UPDATE (published after June 1, 2020) groups are demonstrated and compared in Fig. 2 . We also compare the prevalence of OGD between EARLY and UPDATE groups (relative risk).

Three authors (DW, YHC, PCW) reviewed 25 studies and extracted data including publication specifics, patients' collective demographics (gender, age), disease characteristics (onset, duration, severity, recovery), and associated clinical information. Disagreements were solved through repetitive discussions. Studies that reported OGD both independently and with clear numerators/denominators were used for data synthesis.

Statistical analysis was performed using MedCalc for Windows, version 19.4 (MedCalc Software, Ostend, Belgium). A forest tree plot (Fig. 3 ) was used to demonstrate the pooled-prevalence (with 95% confident interval) of OGD. We estimated the prevalence of OGD and compared it with that of other OGD-related symptoms, the weighted summary proportion under the fixed and random effects model was assessed. Publication bias was assessed by funnel plot asymmetry and Egger's regression test. Whenever there was heterogeneity, a random effects model was selected. Cochran's Q and I 2 tests were used to evaluate the heterogeneity with the criteria P<0.1 or larger I 2 values to show increasing heterogeneity [16] . We compare the prevalence of OGD between subgroups with and without objective smell/taste evaluation (relative risk).

In total, we identified 198 papers using key words and an extended manual search; 25 papers were retained for full text evaluation and meta-analysis/data synthesis. The literature selection algorithm is shown in Fig. 1 . All appropriate criteria, and a summary of study characteristics is detailed in Table 1 . Pooled, the studies included olfactory and gustatory information from 7,778 patients (average age 46.78, 56.9% female). The studies were conducted in Europe (16, 64%), North America (5, 20%), Asia-Other than China (3, 12%), and China (1, 4%). 12 (48%) studies were published prior to May 31, 2020 (EARLY group); while the remaining studies were published between June 1, 2020 and September 30, 2020 (UPDATE group).

In total, 20 studies were of level IV evidence, and 5 studies were of level III evidence (retrospective, case control study). The quality scores ranged from 1 to 7, with a mean score of 2.88±1. 26 

Of the 25 selected studies, 19 reported olfactory dysfunction independently, and 18 reported gustatory dysfunction independently. The pooled prevalence of olfactory dysfunction was 53.56% (range 5.6-100%, 95% CI 40.25-66.61%). The pooled prevalence of gustatory dysfunction was 43.93% (range 1.5-85.18%, 95% CI 28.72-59.74%). (Fig. 3 

Of the 19 studies (76%) reporting prevalence of olfactory and gustatory dysfunction independently, 17 (68%) relied on self-reporting via telephones, computers, or mobile devices; 6 (24%) used validated questionnaires; 2 (8%) used chemo-sensory strips.

Associated nasal symptoms were reported in 16 studies (64% 

The reported onset of OGD ranged from 2 to 23 days, with a median of 5. 

Associated risk factors of OGD were reported in 11 studies (44%). They reported the prevalence of smoking (10.49%, 95% CI 6.4-15.45%), asthma (7.51%, 95% CI 4.43-11.32%), chronic obstructive pulmonary disease (3.86%, 95% CI 1.09-8.22%), and allergic rhinitis (16.29%, 95% CI 11.03-22.35%).

Heterogeneity tests for OGD indicated that there was high heterogeneity in both olfactory and gustatory dysfunctions, with I 2 being 98.46% (98.14% ~98.73%) and 98.91% (98.69% to 99.08%), respectively. Publication bias tests (Egger's test) had intercepts of -3.6 (-10.8 ~ 3.6, P> 0.05) and -2.3 (-11.5 ~ 6.8, P> 0.05), respectively. (Fig. 4) 

Since its outbreak in Wuhan, China in late 2019, the COVID-19 pandemic has been worse in severity and duration compared to SARS. Early detection of community infection is the key to containing the disease, and many fast RT-PCR test kits have been developed during the pandemic. The biochemical test is crucial in establishing diagnosis. However, test capacity has become a key issue in successful disease containment. To allocate test resources more than in other non-SARS-CoV2 coronavirus infections [18] . Several systematic reviews have reported high prevalence of olfactory (41~74.9%) and gustatory (38.2~81.3%) dysfunctions that postulate the importance of these symptoms [10, 11, 18, 19] . In Giorli et al.'s report, the prevalence of anosmia is third only to fever (rate difference -0.316) and cough (-0.249) in non-hospitalized patients [20] .

As a result, new onset OGD has been recommended as a screening tool by the American Academy of Otolaryngology -Head and Neck Surgery (AAO-HNS) [12] , the British Association of Otorhinolaryngology [21] , and the Centers for Disease Control and Prevention (CDC) [22] . OGD as a predictor of COVID-19 has 97% specificity, 65% sensitivity, 63% positive predictive value, and 97% negative predictive value, as reported by Haehner A et al. [23] With the rapid accumulation of studies investigating COVID-19 symptoms, particularly the unique manifestation of OGD, we felt the need to update our understanding of this matter.

Because the olfactory bulb is considered to be an immunologic barrier to viral infection, understanding the pathophysiology of COVID-19-induced anosmia is important. Emerging evidence indicates that SARS-COV-2 leads to central nervous system complications when it infiltrates the olfactory neuroepithelium [24] and blood brain barrier [25, 26] . Angiotensin converting enzyme 2 (ACE2) is considered to be the primary receptor for SARS-COV-2 virus.

Studies have shown that the olfactory neuroepithelium has elevated ACE2 expression, which suggests that SARS-COV-2 replication enters the central nervous system and induces anosmia via this route [27, 28] . SARS-CoV-2 particles were found in the olfactory bulb of a COVID-19 patient with diffuse CD163-positive macrophage and cytotoxic T lymphocyte infiltration. CD163 is a marker of cytokine storm-induced macrophage activation [24] . More neuroepithelium biopsy specimens are required to prove this hypothesis, however, with the low prevalence of flu-like nasal symptoms (such as nasal obstruction, rhinorrhea, sneezing, etc.) shown in most studies [23, [29] [30] [31] [32] , it is generally agreed that COVID-19-related OGD is sensorineural rather than conductive, though most studies were not able to verify patients' prior rhinology history.

OGD is reported more in ambulatory COVID-19 patients (mild cases), however, due to the wide range of admission criteria and the difficulty in surveying intubated patients (severe cases), the reliability of this characteristic is questionable [5, 31, [33] [34] [35] . Higher OGD prevalence is observed in female and younger patients [29, 30, 36, 37] . This sex and age difference may be attributed to sex and age-related inflammatory and hormonal responses that reflect the lifetime plasticity of OGD [36, 38] . Regarding time course, whether patients can fully recover from OGD after contracting COVID-19 is a point of interest. Most studies reported acute onset and rapid recovery of OGD [39, 40] . Samaranayake reported that 64.5% of olfactory and 54.0% of gustatory symptoms manifested prior to general COVID-19 symptoms [19] . Levinsen reported a recovery rate of 73.3% [41] , which is encouraging. Most studies reported that OGD had significant improvement around 1-2 weeks after disease onset [30, 42, 43] . A 15-day recovery rate of 64% was reported by Chary et al [36] , while 30-day electronic survey and quality-of-life evaluation studies reported >60% and >80% total recovery of OGD [35, 44] . Since the time course might be prognostic, it is important to understand the severity grading and functional deficit of OGD, which were mentioned in only a few of the studies we reviewed [45] [46] [47] [48] [49] .

Prior systematic reviews reported a wide range of OGD prevalence due to the variety of study designs, methodology, sample size, geographic location, and olfactory test validity. Owing to the nature of rapid publication, the studies were of poor quality; only 5 studies were based on controlled study designs. Aside from gender and age, limited patient demographic or clinical information were included. In addition, most of the studies failed to control for or verify other underlying causes of smell and taste dysfunction during the pandemic. The risk of bias are continuously seen in both EARLY and UPDATE publication groups. And, EARLY group had higher risks of olfactory and gustatory dysfunctions than UPDATE group. The validity of the smell test is another critical issue; few studies [5, 52] used an objective chemosensory test.

Our investigation shows that studies with objective smell/taste evaluation tended to have lower OGD prevalence (even though the difference for olfactory function is not statistically significant), this attests the need to obtain reliable OGD information from objective chemosensory test. In general, the extrapolation of this study is limited by the information quality we can extract from the current OGD-related COVID-19 literatures. 

This database study is waived from IRB approval.

The Author(s) declare(s) that there is no conflict of interest. 

Real-time RT-PCR in COVID-19 detection: issues affecting the results

SARS: How Do They Differ? Healthline Web sites

COVID-19 and SARS: Differences and similarities

Modeling the Onset of Symptoms of COVID-19. Front Public Health

Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Olfactory Cleft Measurements and COVID-19-Related Anosmia

Olfactory Bulb MRI and Paranasal Sinus CT Findings in Persistent COVID-19 Anosmia

Olfactory Cleft Width and Volume: Possible Risk Factors for Postinfectious Olfactory Dysfunction

Smell and Taste Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis

The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis

COVID-19 Anosmia Reporting Tool for Clinicians

COVID-19 Anosmia Reporting Tool: Initial Findings

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement

Measuring inconsistency in meta-analyses

Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands

Aggregate Prevalence of Chemosensory and Sinonasal Dysfunction in SARS-CoV-2 and Related Coronaviruses

Sudden onset, acute loss of taste and smell in coronavirus disease 2019 (COVID-19): a systematic review

A Literature Systematic Review with Meta-Analysis of Symptoms Prevalence in Covid-19: the Relevance of Olfactory Symptoms in Infection Not Requiring Hospitalization

Loss of sense of smell as marker of COVID-19 infection

CDC's Diagnostic Test for COVID-19 Only and Supplies

Predictive Value of Sudden Olfactory Loss in the Diagnosis of COVID-19

Ultrastructural Evidence of Direct Viral Damage to the Olfactory Complex in Patients Testing Positive for SARS-CoV-2

Neurological Insights of COVID-19 Pandemic

Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms

Features, Evaluation, and Treatment of Coronavirus (COVID-19). U.S. National Library of Medicine Web sites

SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection

Olfactory and Oral Manifestations of COVID-19: Sex-Related Symptoms-A Potential Pathway to Early Diagnosis

Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based case-control study

New onset of loss of smell or taste in household contacts of home-isolated SARS-CoV-2-positive subjects

Features of anosmia in COVID-19

Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms

Self-reported olfactory loss associates with outpatient clinical course in COVID-19

Olfactory Dysfunction in COVID-19 Patients: Prevalence and Prognosis for Recovering Sense of Smell

Prevalence and Recovery From Olfactory and Gustatory Dysfunctions in Covid-19 Infection: A Prospective Multicenter Study

Chemosensory Dysfunction in COVID-19: Prevalences, Recovery Rates, and Clinical Associations on a Large Brazilian Sample. Otolaryngol Head Neck Surg

COVID-19-Related Anosmia: The Olfactory Pathway Hypothesis and Early Intervention

Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients

Dysfunction in Coronavirus Disease 19 (COVID-19)

Time course of anosmia and dysgeusia in patients with mild SARS-CoV-2 infection

Early recovery following new onset anosmia during the COVID-19 pandemic -an observational cohort study

Smell and taste disorders during COVID-19 outbreak: Cross-sectional study on 355 patients

An Integrated Care Strategy for the Follow-up of Patients With COVID-19-Associated Chemosensory Dysfunction

Smell dysfunction: a biomarker for COVID-19

Olfactory and Gustatory Dysfunction as An Early Identifier of COVID-19 in Adults and Children: An International Multicenter Study

Taste and Smell Impairment in COVID-19: An AAO-HNS Anosmia Reporting Tool-Based Comparative Study

Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19: Prevalence, Severity, Timing, and Associated Characteristics

Do olfactory and gustatory psychophysical scores have prognostic value in COVID-19 patients? A prospective study of 106 patients

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis (Berl)

Clinical and Epidemiological Characteristics of 1,420 European Patients with mild-to-moderate Coronavirus Disease

Objective Olfactory Findings in Hospitalized Severe COVID-19 Patients

Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases